DRAXIN: A Promising Drug Target for Cardiovascular Disease (G374946)

Target Name: DRAXIN

NCBI ID: G374946

DRAXIN

DRAXIN: A Promising Drug Target for Cardiovascular Disease

DRAXIN (AGPA3119) is a drug target (AGPA3119, Angiotensin-converting enzyme 3119) that is being studied for its potential role in treating cardiovascular disease. The AGPA3119 gene is a member of the angiotensin-converting enzyme (ACE) family, which is responsible for regulating the body's blood pressure.

DRAXIN is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a potent inhibitor of the ACE enzyme, which is responsible for breaking down a hormone called angiotensin II. Angiotensin II is a potent vasoconstrictor that can cause blood pressure to rise and increase the risk of cardiovascular disease.

DRAXIN's ability to inhibit the ACE enzyme has made it a promising drug target for the treatment of cardiovascular disease. Studies have shown that high levels of DRAXIN are associated with an increased risk of cardiovascular disease, including heart failure, hypertension, and stroke. By blocking the action of the ACE enzyme, DRAXIN has the potential to reduce the production of angiotensin II and lower blood pressure, which can help to prevent the development of cardiovascular disease.

In addition to its potential use in treating cardiovascular disease, DRAXIN has also been shown to have potential uses in treating other conditions. For example, high levels of DRAXIN have been associated with an increased risk of developing chronic kidney disease, and therefore, DRAXIN has has been shown to be a potential drug target for treatments of chronic kidney disease.

DRAXIN has also been shown to have potential uses in treating other conditions, such as cancer and neurodegenerative diseases. For example, studies have shown that high levels of DRAXIN are associated with an increased risk of developing multiple sclerosis, a neurodegenerative disease. Therefore, DRAXIN has been shown to be a potential drug target for treatments of multiple sclerosis.

In conclusion, DRAXIN is a drug target (AGPA3119, Angiotensin-converting enzyme 3119) that has the potential to treat a variety of conditions, including cardiovascular disease, chronic kidney disease, and neurodegenerative diseases. Studies have shown that DRAXIN is an effective inhibitor of theACE enzyme, and have shown that it has the potential to reduce the production of angiotensin II and lower blood pressure, which can help to prevent the development of cardiovascular disease. Further research is needed to fully understand the potential uses of DRAXIN, and to determine the best way to use it in the treatment of cardiovascular disease and other conditions.

Protein Name: Dorsal Inhibitory Axon Guidance Protein

Functions: Chemorepulsive axon guidance protein required for the development of spinal cord and forebrain commissures. Acts as a chemorepulsive guidance protein for commissural axons during development. Able to inhibit or repel neurite outgrowth from dorsal spinal cord. Inhibits the stabilization of cytosolic beta-catenin (CTNNB1) via its interaction with LRP6, thereby acting as an antagonist of Wnt signaling pathway

The "DRAXIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRAXIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets